Partner search

Company: Canabinote
CIF: 52.198.260/0001-17

Address:	Contact: Flavia Vilhena França
Av. Dra. Nadir Aguiar, 1805 Ribeirão Preto - SP - Brasil 14056-680 +55 (16) 3315-0735	Position: CEO
	Telephone: +55 (11) 97360-9779
	Email: flavia.franca@canabinote.com

Short Company presentation

(R & D guidelines, international activities, etc.)

Canabinote is a Brazilian digital health company focused on clinical decision support and real-world evidence (RWE) for cannabis-based therapies. The platform was designed as a science-driven prescribing system, helping physicians match patient profiles with evidence-based cannabis formulations and monitor outcomes over time.

Our R&D strategy combines:

• **Clinical Decision Support Systems (CDSS)** for therapeutic substances, with specialization in medical cannabis.

• **Data models for real-world evidence (RWE)**, connecting prescription data, patient-reported outcomes, and product characteristics.

• **Interoperability with medical and hospital information systems**, enabled through an API-oriented architecture.

• **Regulation-oriented analytics**, generating structured evidence to support health authorities and industrial partners.

Canabinote is currently expanding its activities toward international collaborations, particularly in countries where medical cannabis programs are being structured or scaled. The company aims to work closely with pharmaceutical manufacturers, hospital networks, and research groups to jointly develop and validate digital tools that make cannabis-based treatments safer, more standardized, and scientifically grounded.

DESCRIPTION OF ITS TECHNOLOGY AND CAPABILITIES IN R & D
(Products, technologies, applications, services, etc.)

Core Technology

Evidence-based medical cannabis prescribing system

- Encodes clinical evidence (randomized clinical trials, observational studies, guidelines) into structured decision rules.

- Assists physicians in selecting indications, formulations, product types, dosage ranges, and titration schemes based on scientific evidence.

- Enables electronic recording of patient notes throughout treatment.

- Tracks treatment progression, titration steps, effectiveness, and adverse events.

- Allows configuration by country/region to comply with local regulations and formularies.

Delivery of Indicators from RWE and Analytics

- **Prescriber/health professional dashboard** with patient quality-of-life indicators, enabling real-time monitoring.

- **Brand/product supplier/pharmaceutical dashboard** with product performance indicators derived from patient monitoring data.

Technological Capabilities

- Design and implementation of modular, cloud-based SaaS platforms for use by healthcare professionals individually or within clinics, hospitals, health operators, and other organizations.

- Design and implementation of the **white-label version** of the platform for medical cannabis product suppliers who wish to structure a decision-support environment for exclusive use, customized with their visual identity.

- Customization of clinical logic to reflect national regulatory frameworks (e.g., list of authorized indications, standardized preparations, prescribing routes).

Applications and Services

- Medical education platform

- Digital prescribing tool

- Remote patient monitoring tool

- Customizable tool for B2B medical cannabis industry suppliers, providing real-world evidence (RWE) on their products through an exclusive environment for healthcare professionals to prescribe and monitor patients treated with their formulations (Canabinote white-label environment)

Development Goals

- Develop APIs and interoperability standards (FHIR-like approach) for integration with electronic health records (EHR), electronic prescribing systems, and pharmacy management software.

- Expand the product-registration tools for hospital pharmacy services, ensuring safe dispensing of compounded preparations with batch documentation and tracking.

- Enhance tools for planning and analyzing observational studies and pragmatic pilot projects involving medical cannabis.

PROPOSED COLLABORATIVE PROJECT IN R & D
(As much detail as possible, both in what it offers and what you want in a potential partner)

Technology offered to international partners

Canabinote offers a configurable digital platform that can be adapted to the medical cannabis ecosystem of the partner country. The platform can be customized with the partner's branding and positioned as an integral component of its B2B value proposition for hospitals, clinics, and healthcare systems, with a strong emphasis on scientific evidence for clinical decision support in medical cannabis prescribing, and in full compliance with applicable regulations on medicines and controlled substances.

The platform's current operational services include:

- Clinical decision support system for prescribing cannabis-based medicines and preparations grounded in scientific evidence.
- Electronic prescribing module with a universal dosage calculator for medical cannabis treatments.
- Data architecture that delivers real-world evidence on the safety and effectiveness of different cannabis products in routine care.
- Configurable code frameworks to meet national regulations, the partner's product portfolio, and local clinical practice.
- Customizable white-label version of the system, enabling the partner to explore subscription-based licensing models for other B2B companies operating in the medical cannabis market.

Technology looking for an international partner

Canabinote is seeking a Spanish industrial partner with the following profile:

- Pharmaceutical or life sciences company holding authorizations in Spain related to medical cannabis (e.g., manufacturing or distribution for medical and scientific use).
- Strong B2B orientation, supplying products or APIs to other companies, hospitals, or healthcare services in Spain and/or across European markets.
- Commitment to innovation and R&D in medical cannabis, participation in clinical or observational research, collaborations with hospitals and universities).
- Interest in integrating digital health solutions into its value proposition, especially tools for: supporting prescribing physicians and pharmacists, structuring treatment pathways, generating clinical data on its products.
- Ability and willingness to co-lead pilot projects in Spanish hospitals/clinics, connecting the digital platform to real-world use of medical cannabis products.

In summary, the ideal partner is a Spanish company already recognized as a European reference in medical cannabis, with a strong industrial base and the ambition to differentiate itself through scientific evidence, data intelligence, and digital tools that improve health outcomes and support regulatory evolution.

Other specifications, requirements, or comments

The collaboration should be structured as a co-development model, in which:

- Canabinote leads the design of the digital platform, tailoring the system to Spanish needs and advancing the outlined development goals.
- The Spanish partner leads the adaptation to the national ecosystem, product modeling, and engagement with local clinical centers.

The partner should be open to creating a long-term partnership strategy, potentially including:

- co-branding models,
- preferential or exclusive rights for the commercial deployment of the platform in Spain (subject to mutually agreed terms),
- and joint exploration of other EU markets in the future.

And both parties should share an interest in producing joint scientific outputs (posters, articles, technical reports) based on data generated through the pilot projects.

The proposed project consists of the joint development and validation, in Spain, of a digital platform for evidence-based prescribing and monitoring of medical cannabis, integrated into the industrial and clinical ecosystem of the Spanish partner.

Key elements:

- Adaptation of the Canabinote platform to the Spanish regulatory and clinical context, including the modeling of authorized medical cannabis products supplied by the partner.

- Design and implementation of pilot projects in hospitals/clinics in Spain, in which physicians and pharmacists will use the platform to support prescribing and monitoring of patients treated with medical cannabis.

- Collection and analysis of real-world data, assessing safety, effectiveness, and usage patterns of different products in routine clinical practice.

- Development of RWE-based tools and reports to support decision-making by physicians, healthcare services, and the partner company, contributing to future regulatory discussions.

GOBIERNO
DE ESPAÑA

MINISTERIO
DE CIENCIA, INNOVACIÓN
Y UNIVERSIDADES

CDTI
INNOVACIÓN

- Creation of a joint partnership plan, enabling the Spanish partner to offer the Canabinote solution as a B2B white-label service to its clients, while Canabinote continues to advance the underlying technology.

The company is particularly interested in strategic partnerships where digital innovation is a main differentiating factor in the medical cannabis field. The ideal collaboration will combine:

- **on the partner's side**, its industrial and market position in Spain; and

- **on Canabinote's side**, its expertise in digital health technology and data science,

to create a reference model for a safe, evidence-based, data-driven use of medical cannabis, with potential for future replication in other countries.

General comments:

- By sending this information document authorizing its dissemination.
- A profile of the company may be attached